

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NIDN 10370 CON

In Re Application Of: **Roald Skurtveit, et.al.**

Serial No.
10/717197

Filing Date
November 19, 2003

Examiner
To Be Assigned

Group Art Unit
1617

Title: **ULTRASOUND CONTRAST AGENT DISPERSIONS COMPRISING GAS AND DESTABILISING AGENT**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NIDN 10370 CON

In Re Application: **Roald Skurtveit, et.al.**

Serial No.	Filing Date	Examiner	Group Art Unit
10/717197	November 19, 2003	To Be Assigned	1617

ULTRASOUND CONTRAST AGENT DISPERSIONS COMPRISING GAS AND DESTABILISING

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: _____)
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on <u>4-7-04</u> with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 Signature of Person Mailing Correspondence
Lori B. Allaire Typed or Printed Name of Person Mailing Certificate


***This certificate may only be used if paying by deposit account.**

Signature

Dated: 4/6/04

Li Cai
Reg. No. 45, 629
Amersham Health, Inc.
101 Carnegie Center
Princeton, NJ 08540
(609) 514-6418

cc:



FORM PTO 449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. NIDN-10370 CON	SERIAL NO. 10/717,197
	APPLICANT Skurtveit et al.	
	FILING DATE 19 November 2003	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 5,733,572	03/1998	Unger et al.			
	US 5,846,517	12/1998	Unger et al.			
	US 6,375,931	04/2002	Ostensen et al.			
	US 5,685,310	11/1997	Porter et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/17324	04/1998	WIPO				
	WO 95/07072	03/1995	WIPO				
	WO 95/03835	02-1995	WIPO				
	WO 95/16467	06-1995	WIPO				
	WO 98/10799	03/1998	WIPO				
	EP 0212568	03/1987	EPO				
	EP 0365467	04/1990	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Wey K. et al., "Quantification of Myocardial Blood Flow With Ultrasound-Induced Destruction of Microbubbles Administered as a Constant Venous Infusion", Circulation, vol. 5, no. 97, 10 February 1998, pages 473-483, XP002077428
	Wey K. et al., "Use of Microbubble Destruction as a Novel Approach for Quantification of Myocardial Perfusion With Contrast Echocardiography During Venous Infusion of Contrast", Journal of the American College of Cardiology, 1 February 1997, XP002077429
	Vandenberg et al., "Myocardial risk area and peak gray level measurement by contrast echocardiography: Effect of microbubble size and concentration, injection rate, and coronary vasodilation", American Heart Journal vol 115, 1998, page 733-739, XP002112966
	International Search Report dated 13 September 1999 for PCT/GB99/01228

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.